tbuckley/cabot-search huggingface dataset:
A LAWYER DISBARRED.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selected Articles from This Issue
Journal: Clinical Cancer Research (2021)

Adavosertib (AZD1775) is a Wee1 kinase inhibitor that abrogates G1/S and G2/M cell cycle arrest, leading to replication stress and, ultimately, tumor cell death. Takebe and colleagues performed a clinical trial of once-daily adavosertib in patients with solid tumors. Adavosertib was well tolerated, and plasma exposures were similar to a twice-daily regimen. Six patients (14%) showed a partial response. Elevated tumor CCNE1 mRNA expression was identified as a potential biomarker for response, particularly in ovarian and endometrial cancers. These results suggest adavosertib monotherap. may hold promise in patients with advanced solid tumors when combined with biomarker selection using CCNE1 expression as a precision medicine approach to induce synthetic lethality.Checkpoint inhibitors demonstrated clinically meaningful antitumor activity and a manageable safety profile in chemotherapy-refractory gastroesophageal cancer (GEC). Lei and colleagues performed an exploratory analysis of the CheckMate 032 GEC cohort comparing the clinical utility of PD-L1, assessed using percentage of tumor cell (%TC) versus combined positive score (CPS), to predict nivolumab ± ipilimumab treatment efficacy. The analysis demonstrated that increased objective response and overall survival were observed with CPS compared with %TCs at higher cut-offs. Additionally, the study showed that multiple inflammatory gene expression signatures, including the four-gene signature of CD274, CD8A, LAG3, and STAT1, were associated with response, warranting further investigation.Maximal safe resection is an important first step to the successful management of glioma patients. Intraoperative fluorescent labeling is effective in maximizing the extent of tumor resection while minimizing the risk of excessive resection of the non-tumorous surrounding brain; however, the currently used probe lacks sufficient sensitivity and is not able to be readministered. Kitagawa and colleagues established a novel fluorescent labeling system for rapid intraoperative detection of glioblastoma using a topical, proline-arginine hydroxymethyl rhodamine green-based probe (PR-HMRG). This probe successfully distinguished tumor from peritumoral tissues in animal studies due to Calpain-1 protease activity. Further work will be needed to determine this probe's clinical applicability.Combining immune checkpoint blockade (ICB) with radiation therapy is considered a promising strategy, but only a subset of patients responds to treatment. Chen and colleagues assessed changes in immune infiltration after chemoradiotherapy (CCRT) in patients with cervical cancer. CCRT led to increased CD8+ T-cell infiltration and interferon induction, but only in a subset of patients. This heterogeneity in antitumor immunity and interferon response validates the observation that combination CCRT and ICB will only be of clinical benefit to certain patients. Additional studies are needed to identify biomarkers for patients who will benefit from CCRT.
La séroréaction blennorragique
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Frédéric E. Lecouvet, Bruno C. Vande Berg, François Jamar, Bertrand Tombal, Jacques Jamart, Bertrand Janne d'Othée
Journal: Journal of Clinical Oncology (2008)

with metastases, these were interpreted as benign lesions; in patients without metastases, these were interpreted as metastases.The authors concede that this may have lowered the sensitivity and specificity that they calculated.But, more than that, this approach does not at all reflect clinical practice.Faced with an equivocal result, one may invoke another technique to try and relieve the uncertainty.Otherwise, one could either count all equivocal findings as metastases, or all as benign.Since it is not known beforehand which patients harbor metastases and which do not, it is not conceivable that equivocal lesions would be assigned to the metastases group in patients without metastases, and vice versa, as the authors have done in their statistical analysis.Therefore, a far more realistic statistical analysis would take into account two possibilities, one in which all equivocal lesions would be considered as metastases, and another in which all these would be considered as benign.In the first case, the sensitivity would be high at the cost of the specificity, and in the second case, the reverse would be true.In fact, this would constitute a simple ROC analysis, the results of which would far better reflect clinical use than does the analysis provided by the authors.Third, when x-rays did not show either a benign or a malignant explanation to equivocal bone scan findings, these results were classified by the authors as equivocal or discrepant.In clinical practice, a normal bone radiograph associated with an abnormal scan is highly suggestive of malignant disease, as exemplified by the case presented by the authors in their Figure 1. 5 In conclusion, both the failure to perform SPECT, which may help to reduce the number of equivocal findings, and the inappropri-ate statistical treatment of equivocal results, may have distorted the conclusions from Lecouvet's study.
Survey Finds US Women Knowledgeable About Breast Cancer
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inappropriate and appropriate selection of 'peers' in grant review
Authors: S. A. Glantz
Journal: JAMA (1994)

<h3>Objective.</h3> —To assess the members of the California Tobacco Related Diseases Research Program Behavioral and Public Health Research on Tobacco Study Section and those of the Agency for Health Care Policy and Research (AHCPR) Dissemination Study Section as "peers" to review tobacco policy research. Both study sections reviewed a similar grant application on tobacco policy research written by one of us (S.A.G.). <h3>Design.</h3> —Search of MEDLINE for 1989 through 1993 with the keyword<i>tobacco</i>for Tobacco Related Diseases Research Program and AHCPR reviewers. As a control, the National Institutes of Health Cardiovascular Study Section, which reviewed a ventricular function grant submitted by the same author with the keyword<i>heart</i>, was analyzed. <h3>Setting.</h3> —Not applicable. <h3>Patients or Other Participants.</h3> —Study section members. Interventions.—None. <h3>Main Outcome Measures.</h3> —Publications by study section members in areas germane to the proposal being reviewed. <h3>Results.</h3> —Six (33%) of 18 Tobacco Related Diseases Research Program reviewers had no "tobacco" publications (median, two publications; interquartile range, zero to four). The members' "tobacco" publications concentrated on well-controlled experimental interventions on smoking cessation and prevention strategies, not tobacco policy. Only one member had primary expertise in tobacco policy research. None of the AHCPR reviewers had "tobacco" publications. All 31 (100%) of the National Institutes of Health reviewers had "heart" publications (median, nine publications; interquartile range, seven to 19). Five members had a primary interest in the subject of the National Heart, Lung, and Blood Institute application. <h3>Conclusions.</h3> —Study section members' professional interests play a critical role in the level of interest and enthusiasm they will have for a proposal, which affects the priority score. In contrast to the study section that reviewed the heart grant, the study sections that reviewed the tobacco control grant were not "peers." The membership of these review committees has effectively precluded research on tobacco control policy. (<i>JAMA</i>. 1994;272:114-116)
Juvenile gout.
Authors: B L Treadwell
Journal: Annals of the Rheumatic Diseases (1971)

<h3>ABSTRACT</h3> New therapeutic compounds go through a preclinical drug cardiotoxicity screening process that is overly conservative and provides limited mechanistic insight, leading to the misclassification of potentially beneficial drugs as proarrhythmic. There is a need to develop a screening paradigm that maintains this high sensitivity, while ensuring non-cardiotoxic compounds pass this phase of the drug approval process. In this study, we develop an <i>in vitro-in silico</i> pipeline using human induced stem-cell derived cardiomyocytes (iPSC-CMs) to address this problem. The pipeline includes a model-guided optimization that produces a voltage-clamp (VC) protocol to determine drug block of seven cardiac ion channels. Such VC data, along with action potential (AP) recordings, were acquired from iPSC-CMs before and after treatment with a control solution or a low-, intermediate-, or high-risk drug. We identified significant AP prolongation (a proarrhythmia indicator) in two high-risk drugs and, from the VC data, determined strong ion channel blocks that led to the AP changes. The VC data also uncovered an undocumented funny current (I<sub>f</sub>) block by quinine, which we confirmed with experiments using a HEK-293 expression line. We present a new approach to cardiotoxicity screening that simultaneously evaluates proarrhythmia risk (e.g. AP prolongation) and mechanism (e.g. channel block) from iPSC-CMs.
Incorrect Answer in CME Online Quiz Questions
Authors: Anick Bérard, Takoua Boukhris
Journal: JAMA Pediatrics (2016)

Sari L. Reisner, ScD; Katie B. Biello, PhD, MPH; Jaclyn M. White Hughto, MPH; Lisa Kuhns, PhD, MPH; Kenneth H. Mayer, MD; Robert Garofalo, MD, MPH; Matthew J. Mimiaga, ScD, MPH
Whiplash Injuries
Authors: Alexander Gode
Journal: JAMA (1963)

<h3>To the Editor:</h3> —Dr. Mathews' description of the procedure used in administering the<i>coup de lapin</i>is correct and mine was wrong. The rabbit is held by the hind legs, not by the ears. I have never performed the operation and have not had a chance to watch it these 50 yr or more. That may explain but will not excuse my lapse of memory. I just hope that no reader of "Just Words" mistakes me for an expert rabbit-puncher and follows my wrong-way-round directives.
Prophylaxis of recurrent rheumatic fever. Therapeutic-continuous oral penicillin vs monthly injections
Authors: A. R. Feinstein
Journal: JAMA (1968)

For preventing recurrences of rheumatic fever, a repetitive oral penicillin regimen was planned to mimic the action of monthly injections of long-acting penicillin G benzathine. The oral regimen (TCP) contained a<i>therapeutic</i>high level dose for the first ten days of each month, and a<i>continuous</i>low level dose for the remainder of the month. In 343 young rheumatic patients, observed during four calendar years, the group receiving injections had a streptococcal infection attack rate of 6.6 per 100 patient-years, and a rheumatic recurrence rate of 0.6%. For patients receiving TCP, the corresponding rates were 22.7% and 4.8%; these rates were higher than the injection rates even when assessed in a subgroup of patients who maintained TCP with excellent fidelity. The TCP results were not significantly different from those of previously tested oral regimens, in which lower doses of penicillin were used.
Abstract 4870: Dedicator of cytokinesis-x promotes chemo and radioresistance of gastric cancer by modulating WNT signaling and cancer stem cell traits
Authors: Hsiang-Cheng Chi, Kwang-Huei Lin
Journal: Cancer Research (2019)

Abstract Prognosis of gastric cancer (GC) remains poor and the key players in its molecular pathogenesis are unknown at present. There is therefore a critical need to identify novel prognostic factors of GC. Dedicator of cytokinesis represents a protein family belonging to atypical Rho guanine nucleotide exchange factors (GEF) for Rac and/or Cdc42 GTPases. Dedicator of cytokinesis-x, a member of the Dock-C subfamily, exchanges GDP for GTP for Rac1 and Cdc42, both in vitro and in vivo. Here, we identified Dedicator of cytokinesis-x as an independent biomarker for GC prognosis. Elevated Dedicator of cytokinesis-x expression was associated with significantly shorter cumulative survival in both univariate and multivariate analyses. Moreover, higher dedicator of cytokinesis-x expression is positively correlated with tumor size, depth of invasion, lymph node metastasis, vascular invasion and pathological stage. To establish the downstream effectors of dedicator of cytokinesis-x, we analyzed the genes in relation to dedicator of cytokinesis-x expression using three independent clinical GC cohorts. Genes displaying a positive correlation with dedicator of cytokinesis-x were subsequently subject to gene ontology analysis and shown to be significantly involved in the WNT/β-catenin signaling pathway. Depletion of dedicator of cytokinesis-x suppressed cell proliferation, chemo- and radio-resistance, metastasis, oncosphere formation ability and tumorigenicity as well as expression of gastric cancer stem cell (CSC) markers. Dedicator of cytokinesis-x depletion was accompanied by a concomitant decrease in CD44, CD133 and nuclear β-catenin expressions. Moreover, interactions between dedicator of cytokinesis-x and β-catenin were observed in the nucleus of GC cells. This finding suggested that dedicator of cytokinesis-x may act as a tumor promoter through WNT/β-catenin activation. Citation Format: Hsiang-Cheng Chi, Kwang-Huei Lin. Dedicator of cytokinesis-x promotes chemo and radioresistance of gastric cancer by modulating WNT signaling and cancer stem cell traits [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4870.
Acute Flaccid Paralysis Associated With Circulating Vaccine-Derived Poliovirus—Philippines, 2001
Journal: JAMA (2002)

Three cases of acute flaccid paralysis (AFP) associated with circulating vaccine-derived poliovirus (cVDPV) isolates were reported in the Philippines during March 15-July 26, 2001. The first case-patient, a child aged 8 years from northern Mindanao island (500 miles south of Manila) who had received 3 doses of oral polio vaccine (OPV), had onset of paralysis on March 15. A second child, aged 3 years from Laguna province on Luzon island (60 miles south of Manila) who had received 3 OPV doses, presented with signs of meningitis but no paralysis on July 23. A third child, aged 14 months from Cavite province (25 miles from Manila and 45 miles north of Laguna province) who had received 2 OPV doses, had onset of paralysis on July 26. No patients had traveled outside of their province of residence since birth. Characterization of isolates from the three patients revealed type 1 polioviruses derived from Sabin vaccine strain type 1, with a 3% genetic sequence difference between Sabin 1 vaccine and vaccine-derived poliovirus (VDPV) isolates. The three polioviruses are not identical but are closely related (>99% sequence homology); they also appear to share an identical recombination site with a nonpolio enterovirus in the noncapsid region of the genome.
Notice to Readers: Revised Recommendations for Responding to Fecal Accidents in Disinfected Swimming Venues
Journal: JAMA (2008)

3 years.Interviews with families when they brought their infants back to general hospital A for screening, revealed no other exposures to pertussis.No secondary cases of pertussis among HCWs at either general hospital A or children's hospital A were discovered.After HCW A was furloughed and treated, no new cases of pertussis were identified during September-October 2004 in infants born at general hospital A.
La enfermedad diverticular de la próstata: Su estudio como "infección focal" de la próstata
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.
Authors: Anna M. Varghese, Juber Ahamad A Patel, Yelena Yuriy Janjigian, Fanli Meng, S Duygu Selcuklu, Catherine Zimel, David Michael Hyman, Gopa Iyer, Brian Houck-Loomis, Ghassan K. Abou-Alfa, Michael F. Berger, Maeve Aine Lowery
Journal: Journal of Clinical Oncology (2019)

4096 Background: FGFR2 alterations are present in 14% of cholangiocarcinomas (CCA) and are promising targets of investigational FGFR-directed therapies. Cell-free DNA profiling has emerged as a non-invasive approach to monitor disease and longitudinally characterize tumor evolution. We describe the use of circulating tumor DNA (ctDNA) among patients (pts) with FGFR2-altered CCA receiving FGFR-targeted therapy in the identification of acquired FGFR2 mutations (mut) at resistance. Methods: Serial blood samples were collected from 8 pts with FGFR-altered CCA for ctDNA isolation and next generation sequencing. Plasma ctDNA collected at baseline and resistance to FGFR-targeted therapy were sequenced using a custom ultra-deep coverage cfDNA panel, MSK-ACCESS, incorporating dual index primers and unique molecular barcodes to enable background error suppression and high-sensitivity mut detection. The assay was enhanced to include all protein-coding exons and relevant introns of FGFR2. In 5/8 pts, genomic profiling of an initial tumor biopsy was performed. Results: 8 pts with FGFR2-altered CCA (7 gene fusions, 1 amplification) were treated with FGFR-targeted therapies. 7/8 pts exhibited stable disease or partial response. 19 total acquired mut in FGFR2 were detected at resistance in 5/8 pts (between 1-9 unique mut identified in each sample). All mut were located in the kinase domain. Conclusions: Acquired mut in FGFR2 are seen in pts who have developed resistance to targeted therapy. CtDNA can be used to identify these mut at the time of acquired resistance. The multitude of FGFR2 mut observed within individual pts suggest heterogeneity and evolutionary convergence of resistance mechanisms. Our results illustrate the utility of ctDNA as a less invasive way to monitor for signs of resistance and to identify other potential targetable alterations. [Table: see text]
DISEASE AS AN AFTERMATH OF WAR
Journal: JAMA (1923)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal